GlassScriptPhysician profile
Christopher Scott Crooker
NPI 1609801018
$19,184.03
in general payments reported to CMS, 2019-2025
75 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,633 · 2020: $3,154 · 2021: $3,669 · 2022: $2,486 · 2023: $2,590 · 2024: $2,529 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171 · Education: $70.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,171.22 |
| Education | $70.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,050.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,582.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,509.84 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,174.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,026.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $954.70 | 2019-2025 | |
| Amarin Pharma, INC. | $681.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $679.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $596.05 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $555.74 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $537.50 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.54 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $484.39 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $469.35 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.13 | 2020-2024 | Xifaxan, Trulance |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Crooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.